Test Bank For Clayton’s Basic Pharmacology for Nurses 19th EditionhiB y Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Comple te

Test Bank For Clayton’s Basic Pharmacology for Nurses 19th EditionB
M M M M M M M M M i
h




My Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Compl
M M M M M M M M M



e teM

,Chapter 01: Drug Definitions, Standards, and Information Sources Willihnga
M M M M M M M M

n z: Clayton’s Basic Pharmacology for Nurses, 19th Edition
M M M hi M M M M




MULTIPLEMCHOICE

1. WhichMnameMidentifiesMaMdrug listedMbyMtheMUSMFood hi


ManMdDrugMAdministrationM(FDA)?
hi


a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:M C
TheMofficialMnameMisMtheMnameMunderMwhichMaMdrugMisMliste
dMbyMtheMFDA.MTheMbrandMname,MorMtrademark,MisMtheMnam
eMgivMenMtoMaMdrugMbyMitsMmanufacturer.MTheMnonproprietar
y,MorMgenMeric,MnameMisMprovidedMbyMtheMUnitedMStatesMAdo
ptedMNamesMCouncil.

DIF: CognitiveMLevel:MKnowledge REF:M p.M 9
OBJ:M1NAT:MNCLEXMClientMNeedsMCategory:MSafe,MEffectiveMCarMeEnvir hi


onmentMTOP:MMMMNursingMProcessMStep:MAssessment
CON:
PatientM Education

2. WhichMsourceMcontainsMinformationMspecificMtoMnutritionalMsupplements?
a. USPMDictionaryMofM USANM &InternationalM DrugMNames
b. NaturalMMedicinesMComprehensiveMDatabase
c. UnitedMStatesMPharmacopoeia/NationalMFormularyM(USPNF)
d. DrugMInteractionMFacts
ANS:M C
UnitedMStatesMPharmacopoeia/NationalMFormularyMcontainsMinformationMspecificMtoMnutrition
alMsupplements.MUSPMDictionaryMofMUSANM &MInternationalMDrugMNamesMisMaMcompilationMofM
hi


drugMnames,MpronunciationMguide,MandMpossibleMfutureMFDAMapprovedMdrugs;MitMdoesMnotMinc
hi


ludeMnutMritionalMsupplements.M NaturalMMedicinesMComprehensiveMDatabaseMcontains
evidence-
basedMinformationMonMherbalMmedicinesMandMherbalMcombinationMproducts;MitMdoesMnotinclude hi


MinfMormationMspecificMtoMnutritionalMsupplements.MDrugMInteractionMFactsMcontainsMcompre

hensiveMinformation onMdrugM interactionMfacts;MitM doesMnotM includeMnutritionalMsupplements.
hi




DIF:MMM CognitiveMLevel:MKnowledge REF:MMM p.M4
OBJ:M3NAT:MM NCLEXMClientM NeedsM Category:MPhysiologicalMInte
hi


grity
TOP: Nursing ProcessMStep:MAssessment CON:MMMNutritionM|MPatientM Education
hi




3. Which drug referenceMcontainsMdrugMmonographsMthatMdescribeMallMdrugsMinMaMtherapeuticMclass?
hi hi


a. DrugMFactsMandMComparisons

,TestMBankM ForM Clayton’sM BasicMPharmacologyMforM NursesM 19thM E 3
ditio
b. DrugMInteractionMFacts
c. Handbook onMInjectableMDrugs
hi


d. Martindale—TheMCompleteMDrugMReference

ANS:M A
DrugMFactsMandMComparisonsMcontainsMdrugMmonographsMthatMdescribeMallMdrugsMin
MatMherapeuticMclass.MMonographsMareMformattedMasMtablesMtoMallowMcomparisonMofsi
hi


milarprModucts,MbrandMnames,Mmanufacturers,McostMindices,MandMavailableMdosageMfor
msMOnlineMversionMisMavailable.

DIF: CognitiveMLevel:MKnowledge REF:MMMp.M 4 TableM1.2 hi


OBJ: 3 NAT:MM NCLEX Client Needs Category:MPhysiologicalMIntegrity
hi hi hi


TOP: Nursing ProcessMStep:MAssessment CON:MMMSafetyM|PatientM EducationM|ClinicalMJudgment
hi




4. WhichMdrug referenceM containsM monographsMaboutM virtuallyMeverysingle-
hi


Mentitydrug availableinMtheMUnitedMStatesMandMdescribesMtherapeuticMusesMofMdrugs,Mincludi
hi hi


ngMaMpprovedMandMunapprovedMuses?
a. Martindale:MTheMCompleteMDrug Reference hi


b. AHFSMDrugMInformation
c. DrugM Reference
d. DrugMFactsMandMComparisons
ANS:M B
AHFSMDrugMInformationMcontainsMmonographsMaboutMvirtuallyMeveryMsingle-
entityMdrugMavailableMinMtheMUnitedMStatesMandMdescribesMtherapeuticMusesMofMdrugs,M including
MapMprovedMandunapprovedMuses. hi




DIF: CognitiveMLevel:MKnowledge REF:MMMp.M 4 TableM1.2 hi


OBJ: 3 NAT:MM NCLEX Client NeedsMCategory:MPhysiologicalMIntegrity
hi hi


TOP: NursingMProcessMStep:MPlanning CON:M SafetyM|PatientM EducationM|ClinicalMJudgment

5. WhichMonlineMdrugMreferenceMmakesMavailableMtoMhealthcareMprovidersMand theMpublicMa
hi


MstaMndard,Mcomprehensive,Mup-to-
dateMlookMupMandMdownloadableMresourceMaboutMmedicines?
a. AmericanMDrugMIndex
b. AmericanM HospitalM Formulary
c. DailyMed
d. DrugMReference
ANS:M C
DailyMedMmakesMavailableMto healthcareMprovidersMandMtheMpublicMaMstandard,Mcomprehensi
hi


ve,Mup-to-
hi


dateMlookMupMandMdownloadableMresourceMaboutMmedicines.MTheMAmericanMDrugMIndexMisnotMa hi


pMpropriateMforMpatientMuse.MTheMAmericanMHospitalMFormularyMisMnotMappropriateMforMpatie
ntM us
e. TheMdrugMreferenceM isM notM appropriateMforMpatientM use.

DIF: CognitiveMLevel:MKnowledge REF: p.M3M |Mp.M4
OBJ:M3NAT:MM NCLEXMClientM NeedsM Category:MPhysiologicalMInte
hi


grity
TOP:MMNursing ProcessMStep:MImplementation
hi


CON:M SafetyM|PatientMEducationM|MClinicalMJudgment

6. WhichMlegislationMauthorizesMtheMFDAMtoMdetermineMtheMsafetyofMaMdrugMbeforeMitsMmarketing?
a. FederalMFood,MDrug,MandMCosmeticMActM(1938)
b. DurhamMHumphreyMAmendmentM (1952)

, TestMBankM ForM Clayton’sM BasicMPharmacologyMforM NursesM 19thM E 4
ditio
c. ControlledMSubstancesMAct (1970) hi


d. KefauverMHarrisMDrug AmendmentM(1962) hi




ANS:M A
TheMFederalMFood,MDrug,MandMCosmeticMActMofM1938MauthorizedMtheMFDAMtoMdetermineMthe
MsafMetyMofMallMdrugsMbeforeMmarketing.M LaterMamendmentsMandMactsMhelpedMtightenM FDAMco

ntrolManMdMensureMdrugMsafety.MTheMDurhamMHumphreyMAmendmentMdefinesMtheMkindsMofMd
rugsMthatMcanMnotMbeMusedMsafelyMwithoutMmedicalMsupervisionMandMrestrictsMtheirMsaleMtoMpre
scriptionMbyMaMlicMensedMpractitioner.MTheMControlledMSubstancesMActMaddressesMonlyMcontrol
ledMsubstancesMandthMeirMcategorization.MTheMKefauverMHarrisMDrugMAmendmentMensuresMdr
hi


ugMefficacyMandMgreaterdrMugMsafety.MDrugMmanufacturersMareMrequiredMtoMproveMtoMtheMFDA
MtheM effectivenessMofMtheirM proMductsMbeforeM marketingMthem.




DIF: CognitiveMLevel:MKnowledge
REF:Mp.M5MTableMl.3MOBJ: 5
NAT:MNCLEXMClientMNeedsMCategory:MPhysiologicalMInteg
ritMyTOP:M NursingMProcessM Step:MAssessment
CON:M SafetyM|PatientM EducationM|MEvidenceM|MHealthMCareMLaw

7. WhichMclassificationMdoesMmeperidineM(Demerol)MfallMunder?
a. I
b. II
c. III
d. IV
ANS:M B
MeperidineM(Demerol)MisMa ScheduleMIIMdrug;MitMhasMaMhighMpotentialMforMabuseMandMmayMlea
hi


dMtoMsevereMpsychologicalMandMphysicalMdependence.MScheduleMI drugsMhaveMhighMpotentialMfor
hi hi


MabuseMandMnoM recognizedMmedicalMuse.MScheduleM IIIMdrugsMhaveMsomeMpotentialMforMabuse.M
hi


UseMmayMlMeadMtoMlowMtoMmoderateMphysicalMdependenceMorMhighMpsychologicalMdependence
.MScheduleMIVMdrugsMhaveMlowMpotentialMforMabuse.MUseMmayMleadMtoMlimitedMphysicalMorMps
ychologicalMdepenMdence.

DIF: CognitiveMLevel:MKnowledge REF: p.M10
OBJ:M2NAT:MMNCLEXMClientMNeedsMCategory:MSafe,MEffectiveM
hi


CarMeMEnvironment
TOP: NursingMProcessMStep:MAssessment CON:M PatientM EducationM|AddictionM|Pain

8. WhichMactionMwouldMtheMFDAMtakeMtoMexpediteMdrugMdevelopmentM andMapprovalMforManMoutb
reakMofMsmallpox?
hi


a. ListMsmallpoxMasMaMhealthMorphan disease. hi


b. OmitMthe preclinicalMresearchMphase.
hi


c. ExtendMtheMclinical researchMphase. hi


d. FastMtrackMthe investigationalMdrug.
hi




ANS:M D
OnceMtheMInvestigationalMNewMDrugMApplicationMhasMbeenMapproved,MtheMdrugMcanMreceiveM
higMhestMpriorityMwithinMtheMagency,MwhichMisMcalledMfastMtracking.MAMsmallpoxMoutbreakMw
ouldMbecMomeMaMpriorityMconcernMinMtheMworld.MOrphanMdiseasesMareMnotMresearchedMinMaMpri
orityMmanner.MPreclinicalMresearchMisMnotMomitted.MExtendingManyMphaseMofMtheMresearchMwo
uldMmeanaMlongerMtimeMtoMdevelopMaMvaccine.MTheMFDAMmustMensureMthatMallMphasesMofMtheMp
hi


reclinicalMandclinicalMreMsearchMphaseM haveM beenMcompletedMinMaMsafeMmanner.
hi




DIF:M M CognitiveMLevel:MKnowledge REF:MMM p.M7 OBJ:M 5